caution is urged on anemia drugs a group of u s kidney disease experts proposed changes in guidelines recommending more cautious use of anemia treatments sold by amgen inc and johnson &amp johnson due to safety concerns a panel established by the national kidney foundation recommended that doctors shouldnt use the drugs too aggressively to fight anemia in kidney disease patients aggressive use of the drugs has been linked to increased risk of death and heart problems the drugs include amgens aranesp and epogen and j&amp js procrit anemia is a common side effect of kidney disease 
